M. B. Alencar

Anti-trypanosomal activity and target validation of the M17 leucyl-aminopeptidase inhibitor DDD00057570 in Trypanosoma cruzi

Background Chagas disease, caused by the parasite Trypanosoma cruzi, affects six to seven million people, and its treatment still relies on two drugs introduced more than fifty years ago, both of limited efficacy and poorly tolerated. The major acidic M17 leucyl-aminopeptidase of T. cruzi is expressed in all developmen...